![Sanofi, Regeneron's Praluent pulls off PCSK9 coup with 29% cut to death risks in most vulnerable patients | Fierce Pharma Sanofi, Regeneron's Praluent pulls off PCSK9 coup with 29% cut to death risks in most vulnerable patients | Fierce Pharma](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1520623740/Sanofibuilding-840x470.jpg?VersionId=kMDhuM0bmAbMLdu6oWl1UpCHFkcx0GDi)
Sanofi, Regeneron's Praluent pulls off PCSK9 coup with 29% cut to death risks in most vulnerable patients | Fierce Pharma
![The office of Sanofi (China) Investment Co., Ltd. is pictured in Shanghai, China, 9 August 2013. Chinese authorities have launched an investigation Stock Photo - Alamy The office of Sanofi (China) Investment Co., Ltd. is pictured in Shanghai, China, 9 August 2013. Chinese authorities have launched an investigation Stock Photo - Alamy](https://c8.alamy.com/comp/W92HPE/the-office-of-sanofi-china-investment-co-ltd-is-pictured-in-shanghai-china-9-august-2013-chinese-authorities-have-launched-an-investigation-W92HPE.jpg)
The office of Sanofi (China) Investment Co., Ltd. is pictured in Shanghai, China, 9 August 2013. Chinese authorities have launched an investigation Stock Photo - Alamy
![Sanofi's Dupixent, amid €10B sales push, posts positive data in chronic spontaneous urticaria | Fierce Pharma Sanofi's Dupixent, amid €10B sales push, posts positive data in chronic spontaneous urticaria | Fierce Pharma](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1627569342/DupixentPackage.jpg/DupixentPackage.jpg?VersionId=ZwEoEpGTEXHLujNlPcOodUUrhktjOrAl)